# TECHNICAL BRIEF: Objective Efficacy Auditing for IL-17A Inhibition
**Focus:** 9-Sigma Bio-Mechanical Verification
**Auditor:** MedStrate Forensic Network

## 1. The Value Proposition
Current biologic efficacy is measured via subjective patient surveys (DLQI/PASI). MedStrate introduces **Deterministic Physics Auditing**. We track the reduction of the **596\text{ Hz}$ impulse** and the **9\text{ Hz}$ resonance** during Bimzelyx administration.

## 2. Actuarial Benefit
Insurance providers currently struggle with "Non-Responder" waste. By licensing
# Update the Manifest with the AI Integration Tier
cat <<EOF > substrate/modules/medstrate/MERCHANT_MANIFEST.znon
{
  "jurisdiction": "MEDSTRATE_REVENUE",
  "merchant_public_address": "[REDACTED_AUDIT_BREACH]",
  "licensing_tiers": {
    "tier_1_patient": "1 POL",
    "tier_2_academic": "2,500 POL",
    "tier_3_physician": "5,000 POL",
    "tier_4_enterprise": "25,000 POL",
    "tier_5_ai_integration": "100,000 POL"
  },
  "tier_descriptions": {
    "tier_5_ai_integration": "Full API/Logic integration for AI platforms (Doctronic, etc.). Includes the 'Sovereign Synthesis' engine for real-time 9-Sigma diagnostic correlation."
  },
  "status": "SECURED_AND_ACTIVE"
}
